Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680882 | 0.82 | ALDH1A1 (0.40) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL1515322 | 0.80 | HMGCR (0.32) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL5174067 | 0.80 | ALDH1A1 (0.39) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL15247980 | 0.78 | KDM4E (0.31) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL24967823 | 0.78 | HMGCR (0.31) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL8962253 | 0.78 | HMGCR (0.31) | HMGCRCHRM1TBXA2RADRA1A | |
| Benzene SCHEMBL1002002 | 0.76 | CCR5 (0.37) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL13521884 | 0.76 | LMNA (0.32) | — | |
| SCHEMBL14394194 | 0.76 | — | — | |
| SCHEMBL26935277 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179665-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | PARABILIS MEDICINES, INC. | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179665-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | IAPP, VIP, NGLY1 | HMGCR 4397/4885CHRM1 4873/4885TBXA2R 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.